Topoisomerase I inhibitors: selectivity and cellular resistance.
暂无分享,去创建一个
Yves Pommier | Y. Pommier | P. Pourquier | Jiaxi Wu | Philippe Pourquier | Y. Urasaki | Jiaxi Wu | G. Laco | Yoshimasa Urasaki | Gary S. Laco
[1] Y. Pommier,et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.
[2] J. Pouliot,et al. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. , 1999, Science.
[3] J. Schellens,et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.
[4] Y. Shiloh,et al. Targeting double-strand breaks to replicating DNA identifies a subpathway of DSB repair that is defective in ataxia-telangiectasia cells. , 1999, Biochemical and biophysical research communications.
[5] Y. Pommier,et al. Apoptotic response to camptothecin and 7‐hydroxystaurosporine (UCN‐01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase i, protein kinase C, Bcl‐2, p53, MDM‐2 and caspase pathways , 1999, International journal of cancer.
[6] C. Bailly,et al. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. , 1999, Cancer research.
[7] K. Fukasawa,et al. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I. , 1999, Cancer research.
[8] G. Verhaegh,et al. Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts. , 1999, Mutation research.
[9] K. Ono,et al. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. , 1999, Molecular pharmacology.
[10] Y. Pommier,et al. Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. , 1999, Nucleic acids research.
[11] C. Morton,et al. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. , 1999, Cancer research.
[12] K. Kohn,et al. Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes , 1999, The EMBO journal.
[13] E. Alnemri,et al. Caspase-mediated Cleavage of DNA Topoisomerase I at Unconventional Sites during Apoptosis* , 1999, The Journal of Biological Chemistry.
[14] J. Champoux,et al. Structural insights into the function of type IB topoisomerases. , 1999, Current opinion in structural biology.
[15] Y. Pommier,et al. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. , 1999, Journal of medicinal chemistry.
[16] M. Poot,et al. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase , 1999, Human Genetics.
[17] T. Litman,et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.
[18] L. Liu,et al. Interaction between human topoisomerase I and a novel RING finger/arginine-serine protein. , 1999, Nucleic acids research.
[19] P. Leder,et al. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] Y. Pommier,et al. Induction of Topoisomerase I Cleavage Complexes by the Vinyl Chloride Adduct 1,N 6-Ethenoadenine* , 1998, The Journal of Biological Chemistry.
[21] Y. Pommier,et al. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.
[22] A. Larsen,et al. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. , 1998, Biochimica et biophysica acta.
[23] M. Wierdl,et al. Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. , 1998, Cancer research.
[24] J. Holden,et al. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. , 1998, Mutation research.
[25] H. Rosing,et al. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. , 1998, Anti-cancer drugs.
[26] J N Weinstein,et al. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. , 1998, Journal of medicinal chemistry.
[27] J. Verweij,et al. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. , 1998, British Journal of Cancer.
[28] S. Sastry,et al. Mechanisms for the Processing of a Frozen Topoisomerase-DNA Conjugate by Human Cell-free Extracts* , 1998, The Journal of Biological Chemistry.
[29] Y. Pommier,et al. Lamin B Phosphorylation by Protein Kinase Cα and Proteolysis during Apoptosis in Human Leukemia HL60 Cells* , 1998, The Journal of Biological Chemistry.
[30] Y. Pommier,et al. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen. , 1998, Biochemistry.
[31] W G Hol,et al. A model for the mechanism of human topoisomerase I. , 1998, Science.
[32] J. Champoux,et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.
[33] M. Ratain,et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.
[34] G. Giaccone,et al. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. , 1998, British Journal of Cancer.
[35] M. Bjornsti,et al. Analysis of comptothecin resistance in yeast: relevance to cancer therapy. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[36] J. Champoux. Domains of human topoisomerase I and associated functions. , 1998, Progress in nucleic acid research and molecular biology.
[37] P. D'Arpa,et al. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines. , 1998, Oncology research.
[38] C. Morton,et al. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. , 1998, Cancer research.
[39] Y. Fujiwara,et al. The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro , 1997, Japanese journal of cancer research : Gann.
[40] L. Liu,et al. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. , 1997, Nucleic acids research.
[41] Y. Pommier,et al. Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps , 1997, The Journal of Biological Chemistry.
[42] F. Goldwasser,et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] P. D'Arpa,et al. Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.
[44] K. Kohn,et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. , 1997, Cancer research.
[45] K. Kohn,et al. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] J. Robert,et al. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[47] G. Ireton,et al. Reconstitution of human topoisomerase I by fragment complementation. , 1997, Journal of molecular biology.
[48] A. Fojo,et al. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. , 1997, Cancer research.
[49] L. Liu,et al. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. , 1997, Biochemical pharmacology.
[50] C. Bailly,et al. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. , 1997, Biochemistry.
[51] K. Kohn,et al. Effects of Uracil Incorporation, DNA Mismatches, and Abasic Sites on Cleavage and Religation Activities of Mammalian Topoisomerase I* , 1997, The Journal of Biological Chemistry.
[52] Y. Pommier,et al. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines , 1997, Cancer Chemotherapy and Pharmacology.
[53] Y. Pommier,et al. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. , 1996, Molecular pharmacology.
[54] J. Wang,et al. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. , 1996, Molecular pharmacology.
[55] A. Burgin,et al. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[56] K. Kohn,et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. , 1996, Cancer research.
[57] B. Stillman,et al. Simian virus 40 large T antigen binds to topoisomerase I. , 1996, Virology.
[58] J. Robert,et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. , 1996, Cancer research.
[59] H. M. Geller,et al. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity , 1996, The Journal of cell biology.
[60] D. Kufe,et al. Identification of a Nucleolin Binding Site in Human Topoisomerase I (*) , 1996, The Journal of Biological Chemistry.
[61] Y. Cheng,et al. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. , 1996, Cancer research.
[62] Y. Pommier,et al. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. , 1996, Oncology research.
[63] K. Cowan,et al. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. , 1995, Cancer research.
[64] K. Kohn,et al. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[65] M. Sehested,et al. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. , 1995, British Journal of Cancer.
[66] Y. Kodera,et al. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT‐11 (A new derivative of camptothecin) , 1995, Journal of surgical oncology.
[67] K. Kohn,et al. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. , 1995, Biochemistry.
[68] Y. Pommier,et al. Eukaryotic DNA topoisomerases I. , 1995, Biochimica et biophysica acta.
[69] Y. Pommier,et al. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. , 1995, Cancer research.
[70] Y. Cheng,et al. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. , 1995, Molecular pharmacology.
[71] Y. Pommier,et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. , 1995, Cancer research.
[72] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[73] B. Giovanella,et al. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. , 1994, Cancer research.
[74] Y. Pommier,et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. , 1994, Journal of the National Cancer Institute.
[75] D. Kufe,et al. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. , 1994, The Journal of biological chemistry.
[76] L. Liu,et al. DNA topoisomerases: essential enzymes and lethal targets. , 1994, Annual review of pharmacology and toxicology.
[77] K. Kohn,et al. Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors , 1994 .
[78] Y. Pommier,et al. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. , 1993, The Journal of biological chemistry.
[79] S. Ellard,et al. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells. , 1993, Carcinogenesis.
[80] M. Bjornsti,et al. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. , 1993, The Journal of biological chemistry.
[81] Y. Pommier,et al. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. , 1993, Molecular pharmacology.
[82] D. Reinberg,et al. DNA topoisomerase I is involved in both repression and activation of transcription , 1993, Nature.
[83] J. Wang,et al. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. , 1993, Cancer research.
[84] H. Strutt,et al. Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. , 1993, Cancer research.
[85] S. Korsmeyer,et al. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. , 1993, Cancer research.
[86] G. Riou,et al. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. , 1993, Biochemical pharmacology.
[87] G. Hofmann,et al. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. , 1993, Oncology research.
[88] N. Saijo,et al. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. , 1992, Biochemical and biophysical research communications.
[89] I. Pastan,et al. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[90] Y. Cheng,et al. Characterization of camptothecin-resistant Chinese hamster lung cells. , 1992, Biochemical pharmacology.
[91] L. Grochow,et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. , 1992, Cancer research.
[92] Y. Pommier,et al. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. , 1992, Cancer research.
[93] L. Liu,et al. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. , 1992, Cancer research.
[94] N. Saijo,et al. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. , 1992, Cancer research.
[95] T. Chung,et al. Topoisomerase IIα and Topoisomerase IIβ Genes: Characterization and Mapping to Human Chromosomes 17 and 3, Respectively , 1992 .
[96] R. Hertzberg,et al. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. , 1992, Oncology research.
[97] K W Kohn,et al. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. , 1991, The Journal of biological chemistry.
[98] P. Jeggo,et al. Cross-sensitivity of γ-ray-sensitive hamster mutants to cross-linking agents , 1991 .
[99] Eric Patterson,et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites , 1991, Nucleic Acids Res..
[100] T. Tsuruo,et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.
[101] R. Hertzberg,et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. , 1990, Molecular pharmacology.
[102] N. Saijo,et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. , 1990, Cancer research.
[103] J. Thacker,et al. DNA-break repair, radioresistance of DNA synthesis, and camptothecin sensitivity in the radiation-sensitive irs mutants: comparisons to ataxia-telangiectasia cells. , 1990, Mutation research.
[104] T. Andoh,et al. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. , 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[105] M. Mattern,et al. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. , 1989, Journal of the National Cancer Institute.
[106] V. Ling,et al. Multidrug resistance in cancer. , 1989, Scientific American.
[107] P. Smith,et al. Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I. , 1989, International journal of radiation biology.
[108] S. Chatterjee,et al. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. , 1989, Cancer communications.
[109] R. Sternglanz,et al. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. , 1988, Molecular pharmacology.
[110] R. Hertzberg,et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. , 1988, Cancer research.
[111] J. Wang,et al. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[112] Y. Suzuki,et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.